COVID-19 Vaccine Market - 2025-2033

January 2026 | 42 pages | ID: C842B6813121EN
DataM Intelligence

Abstracts

COVID-19 Vaccine Market reached US$ 13.43 billion in 2024 and is expected to reach US$ 29.98 billion by 2033, growing with a CAGR of 9.80% during the forecast period 2026-2033.

The COVID-19 Vaccine Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A COVID-19 Vaccine Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Infection Type

• SARS-CoV-2*
• HCoVs
• Others

By Vaccine Type

• mRNA Vaccines*
• Viral Vector Vaccines
• Inactivated Virus Vaccines
• Protein Subunit Vaccines
• Live Attenuated Vaccines
• Others

By Route of Administration

• Intramuscular*
• Subcutaneous
• Oral

By Age Group

• Below 18 Years*
• Above 18 Years

By End-User

• Hospitals *
• Specialty Clinics
• Others

Regional Analysis for COVID-19 Vaccine Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global COVID-19 Vaccine Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Snippet by Infection Type
3.2. Snippet by Vaccine Type
3.3. Snippet by Route of Administration
3.4. Snippet by Age Group
3.5. Snippet by End-User
3.6. Snippet by Region

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Government Support and Initiatives
    4.1.1.2. XX
  4.1.2. Restraints
    4.1.2.1. Limited Manufacturing Capacity
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs

6. BY INFECTION TYPE

6.1. Introduction
  6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  6.1.2. Market Attractiveness Index, By Infection Type
6.2. SARS-CoV-2*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. HCoVs
6.4. Others

7. BY VACCINE TYPE

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  7.1.2. Market Attractiveness Index, By Vaccine Type
7.2. mRNA Vaccines*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Viral Vector Vaccines
7.4. Inactivated Virus Vaccines
7.5. Protein Subunit Vaccines
7.6. Live Attenuated Vaccines
7.7. Others

8. BY ROUTE OF ADMINISTRATION

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Intramuscular*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Subcutaneous
8.4. Oral

9. BY AGE GROUP

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  9.1.2. Market Attractiveness Index, By Age Group
9.2. Below 18 Years*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Above 18 Years

10. BY END-USER

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals *
  10.2.1. Introduction
  10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Others

11. BY REGION

11.1. Introduction
  11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  11.1.2. Market Attractiveness Index, By Region
11.2. North America
  11.2.1. Introduction
  11.2.2. Key Region-Specific Dynamics
  11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.2.8.1. U.S.
    11.2.8.2. Canada
    11.2.8.3. Mexico
11.3. Europe
  11.3.1. Introduction
  11.3.2. Key Region-Specific Dynamics
  11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.3.8.1. Germany
    11.3.8.2. U.K.
    11.3.8.3. France
    11.3.8.4. Spain
    11.3.8.5. Italy
    11.3.8.6. Rest of Europe
11.4. South America
  11.4.1. Introduction
  11.4.2. Key Region-Specific Dynamics
  11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.4.8.1. Brazil
    11.4.8.2. Argentina
    11.4.8.3. Rest of South America
11.5. Asia-Pacific
  11.5.1. Introduction
  11.5.2. Key Region-Specific Dynamics
  11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.5.8.1. China
    11.5.8.2. India
    11.5.8.3. Japan
    11.5.8.4. South Korea
    11.5.8.5. Rest of Asia-Pacific
11.6. Middle East and Africa
  11.6.1. Introduction
  11.6.2. Key Region-Specific Dynamics
  11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. COMPETITIVE LANDSCAPE

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. COMPANY PROFILES

13.1. Pfizer/BioNTech*
  13.1.1. Company Overview
  13.1.2. Product Portfolio
    13.1.2.1. Product Description
    13.1.2.2. Product Key Performance Indicators (KPIs)
    13.1.2.3. Historic and Forecasted Product Sales
    13.1.2.4. Product Sales Volume
  13.1.3. Financial Overview
    13.1.3.1. Company Revenue’s
    13.1.3.2. Geographical Revenue Shares
    13.1.3.3. Revenue Forecasts
  13.1.4. Key Developments
    13.1.4.1. Mergers & Acquisitions
    13.1.4.2. Key Product Development Activities
    13.1.4.3. Regulatory Approvals etc.
  13.1.5. SWOT Analysis
13.2. Moderna, Inc.
13.3. AstraZeneca.
13.4. Johnson & Johnson (Janssen Scientific Affairs, LLC)
13.5. SINOVAC
13.6. CanSino Biologics Inc.
13.7. Novavax.
13.8. Sanofi/GSK
13.9. Beijing Institute of Biological Products Co., Ltd.
13.10. Serum Institute of India Pvt. Ltd.
13.11. Gamaleya Research Institute (*LIST NOT EXHAUSTIVE)

14. APPENDIX

14.1. About Us and Services
14.2. Contact Us